preview

Abbvie Case Summary

Decent Essays

Currently AbbVie carries a small portfolio of drugs consisting of Humira, an arthritis medication, and AndroGel, a testosterone medication. They have multiple other projects in their pipeline and are currently focusing their research and development costs on drugs in the following categories, immunology, virology and oncology. AbbVie had revenues of $10,845,000,000 in 2014 but only managed a net earnings of $963,000,000. This is a -56.9% decrease from the year prior and marks a second consecutive year of reduced net earnings. This is not a particularly accurate depiction of their business practices as AbbVie incurred a $2.2 billion breakup fee for abandoning a merger with Shire PLC. Another notable transaction that Abbvie made in 2015, was

Get Access